Close
Help
Need Help?





JOURNAL

Breast Cancer: Basic and Clinical Research

Detection of Provasopressin in Invasive and Non-invasive (DCIS) Human Breast Cancer Using a Monoclonal Antibody Directed Against the C-terminus (MAG1)

Submit a Paper


Breast Cancer: Basic and Clinical Research 2010:4 15-22

Original Research

Published on 08 Apr 2010

DOI: 10.4137/BCBCR.S0


Further metadata provided in PDF



Sign up for Email Alerts and keep in touch with Breast Cancer: Basic and Clinical Research journal news, updates, events and articles

Abstract

The provasopressin protein (proAVP) is expressed by invasive breast cancer and non-invasive breast cancer, or ductal carcinoma in situ (DCIS). Here we demonstrate the ability of the monoclonal antibody MAG1 directed against the C-terminal end of proAVP to identify proAVP in all cases examined of human invasive cancer and DCIS (35 and 26, respectively). Tissues were chosen to represent a relevant variation in tumor type, grade, patient age, and menopausal status. By comparison, there was 65% positive staining for estrogen receptor, 61% for progesterone receptor, 67% for nuclear p53, and 39% for c-Erb-B2 with the invasive breast cancer sections. Reaction with the normal tissue types examined (67) was restricted to the vasopressinergic magnocellular neurons of the hypothalamus, where provasopressin is normally produced, and the posterior pituitary, where these neurons terminate. The breast epithelial tissue sections on the tissue microarray did not react with MAG1. Previously, we demonstrated that polyclonal antibodies to proAVP detected that protein in all breast cancer samples examined, but there was no reaction with breast tissue containing fibrocystic disease. The results presented here not only expand upon those earlier results, but they also demonstrate the specificity and effectiveness of what may be considered a more clinically-relevant agent. Thus, proAVP appears to be an attractive target for the detection of invasive breast cancer and DCIS, and these results suggest that MAG1 may be a beneficial tool for use in the development of such strategies.



Downloads

PDF  (2.57 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing


What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
testimonial_image
The submission process for manuscript publication in Breast Cancer: Basic and Clinical Research is as easy as A,B,C!  Any minor hiccups I encountered were quickly addressed by Libertas' expert staff via prompt emails, and the timelines between initial submission and publication are surely the shortest on record!  I will definitely be submitting future manuscripts to this journal, and look forward to working with their professional and expert team.
Dr Maggie Laidlaw (Nutrasource Diagnostics Inc, Guelph, Ontario, Canada)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube